Lipaglyn Tablet is a medicine used in the treatment of Noncirrhotic Non-Alcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease (NAFLD) with comorbidities (like obesity, Type 2 Diabetes Mellitus, Dyslipidemia or Metabolic Syndrome), and high cholesterol in diabetes (diabetic dyslipidemia).
LIPAGLYN Tablet contains Saroglitazar which belongs to the class of medicines called peroxisome proliferator activated receptor (PPAR)-alpha and -gamma agonist. It is used for the treatment of diabetic dyslipidaemia and hypertriglyceridemia (increased triglyceride levels in blood) in patients with Type 2 diabetes mellitus not adequately controlled by statin therapy.
LIPAGLYN Tablet acts by increasing the hepatic oxidation of fatty acids which results in significant reduction in synthesis of triglycerides. It also increases the production of good cholesterol and stimulates gene transcription of insulin which controls glucose production, transport and utilization.
The most common side effects of taking this medicine are gastritis, asthenia and pyrexia. Such patients must be monitored for signs and symptoms of congestive heart failure. This medicine should be used with caution in patients with kidney or liver problems, pregnant or breastfeeding.
USES OF LIPAGLYN TABLET
Treats diabetic dyslipidaemia and hypertriglyceridemia in patients with type 2 diabetes mellitus not controlled by statins.
Lipaglyn 4mg - Saroglitazar (4mg)
The information provided here is for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.